Physician profile
Kristi K Orbaugh
NPI 1134191679
$1,308,090.34
in general payments reported to CMS, 2019-2025
24 companies · $251K in 2025
The $251K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $247K · 2022: $269K · 2023: $291K · 2024: $250K · 2025: $251K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $484K · Travel and Lodging: $238K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $25K · Consulting Fee: $24K · Food and Beverage: $21K · Education: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $483,653.91 |
| Travel and Lodging | $238,038.33 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $24,646.19 |
| Consulting Fee | $24,070.50 |
| Food and Beverage | $21,364.47 |
| Education | $204.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $285,910.10 | 2021-2025 | Verzenio |
| Astrazeneca Pharmaceuticals Lp | $246,647.91 | 2021-2025 | Enhertu, Tagrisso, Datroway |
| Gilead Sciences, INC. | $144,922.70 | 2021-2025 | Trodelvy |
| Daiichi Sankyo INC. | $142,535.22 | 2021-2025 | Enhertu, Datroway, Enhertu |
| Incyte Corporation | $141,248.01 | 2021-2025 | Monjuvi, Jakafi |
| Pfizer INC. | $60,683.84 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $48,745.29 | 2021-2025 | Opdivo |
| Cti Biopharma Corp. | $47,581.70 | 2022-2023 | Vonjo |
| Sobi, INC | $36,078.68 | 2022-2025 | |
| Stemline Therapeutics INC. | $33,161.33 | 2024-2025 | Orserdu |
| Genzyme Corporation | $32,445.13 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $19,858.57 | 2022-2025 | Libtayo |
| Coherus Oncology, INC. | $16,471.34 | 2021-2022 | |
| Dova Pharmaceuticals | $11,994.32 | 2021 | |
| Exelixis INC. | $10,428.18 | 2021-2025 | Cabometyx |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $9,455.27 | 2024-2025 | |
| Array Biopharma INC | $5,453.26 | 2021-2025 | Braftovi |
| Celgene Corporation | $5,400.00 | 2022 | |
| Rigel Pharmaceuticals, INC. | $3,300.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $2,592.50 | 2021-2022 | |
| Morphosys, US INC. | $1,925.00 | 2021 | |
| Fresenius Kabi USA, LLC | $672.00 | 2022 | |
| Taiho Oncology, INC. | $480.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristi Orbaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.